Roivant Sciences Ltd. (ROIV)
29.06
+0.56
(+1.98%)
USD |
NASDAQ |
Jun 09, 16:00
29.06
0.00 (0.00%)
After-Hours: 20:00
Roivant Sciences SG&A Expense (Quarterly) : 158.25M for March 31, 2026
SG&A Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
SG&A Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (Quarterly) Benchmarks
| Centessa Pharmaceuticals Plc | 19.85M |
| Aptorum Group Ltd. | 0.2117M |
| Bicycle Therapeutics Plc | 17.44M |
| Adaptimmune Therapeutics Plc | 18.71M |
| Kiniksa Pharmaceuticals International Plc | 61.15M |